The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure； cardiac performance in heart failure； mortality, reinfarction, and/or hospitalization in connection with heart failure； acute heart failure； acute decompensated heart failure； congestive heart failure； severe congestive heart failure； organ damage associated with heart failure (e.g., kidney damage or failure, heart valve problems, heart rhythm problems, and/or liver damage)； heart failure due to left ventricular dysfunction； heart failure with normal ejection fraction； cardiovascular mortality following myocardial infarction； cardiovascular mortality in patients with left ventricular failure or left ventricular dysfunction； left ventricular failure； left ventricular dysfunction； class II heart failure using the New York Heart Association (NYHA) classification system； class III heart failure using the New York Heart Association (NYHA) classification system； class IV heart failure using the New York Heart Association (NYHA) classification system； LVEF ＜ 40% by radionuclide ventriculography； LVEF ≤35% by echocardiography or ventricular contrast angiography； and conditions related thereto.本發明係關於調節β-3腎上腺素受體活性之式(Ia)化合物及其醫藥組合物。本發明化合物及其醫藥組合物係針對可用於治療β-3腎上腺素受體介導之病症的方法，該病症諸如心臟衰竭；心臟衰竭時之心臟效能；與心臟衰竭相關之死亡、再梗死及/或住院；急性心臟衰竭；急性失代償心臟衰竭；充血性心臟衰竭；重度充血性心臟衰竭；與心臟衰竭相關之器官損傷(例如腎臟損傷或衰竭、心瓣膜問題、心律問題及/或肝臟損傷)；因左心室功能障礙所致的心臟衰竭；射血分數正常之心臟衰竭；心肌梗塞後之心血管病死亡；患有左心室衰竭或左心室功能障礙之患者的心血管病死亡；左心室衰竭；左心室功能障礙；使用紐約心臟學會(NYHA)分類系統之II類心臟衰竭；使用紐約心臟學會(NYHA)分類系統之III類心臟衰竭；使用紐約心臟學會(NYHA)分類系統之IV類心臟衰竭；依據放射性核種心室顯像術之LVEF ＜ 40%；依據超音波心動描記術或心室血管造影術之LVEF ≤35%；及與其相關之病況。
